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panuveitis without scleral involvement
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Abstract
Background: The following case emphasizes the importance of including IgG4-related disease (RD) in the
differential diagnosis of intraocular inflammation and multiple cranial nerve palsies.
Results: A 33-year-old man, with a history of idiopathic bilateral panuveitis, presented with a new right pupillary-
sparing partial third nerve palsy, which spontaneously resolved in 2 weeks, but was followed 1 month later, by a
right sixth nerve palsy, which also resolved within a few weeks. Motility disturbance was accompanied by a
decrease in the central acuity in the right eye. Magnetic resonance imaging/angiography (MRI/MRA) demonstrated
a densely enhancing osteodestructive skull base process extending through the cavernous sinus and into the right
superior orbital fissure. Biopsy of the lesion was consistent with IgG4-related disease (RD).
Conclusions: This is the first reported case of IgG4-RD associated panuveitis without scleral involvement,
expanding the list of clinical manifestations of the IgG4-RD.
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Review
A 33-year-old man, with a history of bilateral idiopathic
panuveitis for the past 6 years, presented with a new
onset of binocular oblique diplopia and right ptosis. He
was previously treated with several immunomodulators,
including cyclosporine, mycophenolate mofetil, azathio-
prine, and methotrexate. These agents had failed in con-
trolling his active panuveitis, and he had been receiving
adalimumab infusions every 2 weeks for the past 2 years.
On initial presentation, central acuity was 20/30 in
each eye; extraocular motility testing demonstrated no
adduction and severely restricted supraduction in the
right eye, along with almost complete right-sided ptosis.
Patient was diagnosed with a right pupillary-sparing
partial third nerve palsy. Biomicroscopic examination
revealed bilateral mild to moderate (1/2-1+) anterior
uveitis with a few anterior vitreous cells but no posterior
vitritis. Fundoscopy was grossly normal.
Urgent MRI and MRA of the brain and orbits were
performed and revealed a densely enhancing osteodes-
tructive skull base process, with a lesion centered
around the right sphenoid sinus and extending through
the cavernous sinus into the adjacent meninges and right
superior orbital fissure (Fig. 1a–d). Radiological differen-
tial was between inflammatory (granulomatous non-
infectious or infectious) or, less likely, neoplastic entities.
When the patient was seen 2 weeks later, the right
partial third nerve palsy had completely resolved. A
computed tomography (CT) scanning of the brain and
orbits was performed to further characterize the lesion
and demonstrated a lack of normal inferior wall of the
left sphenoid sinus with the small bone fragments in the
sinus and a small tract extending from the left lateral
sphenoid sinus wall towards the cavernous sinus. There
was also an asymmetric thickening in the left posterior
cavernous sinus extending to the right anterior cavernous
sinus and right orbital apex (Fig. 2).
A month later, the patient started noticing diplopia
again; there was complete absence of right abduction on
exam compatible with a sixth nerve palsy. Central visual
acuity in the right eye had deteriorated to counting
fingers. There was a right RAPD, but no abnormalities
on fundoscopy were noted.
CT scan of the chest, abdomen, and pelvis was obtained
and was reported as normal. Multiple blood tests
(complete blood count, erythrocyte sedimentation rate, C-
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reactive protein, antinuclear antibodies, syphilis screening,
angiotensin-converting enzyme, and tuberculosis purified
protein derivative skin testing) were all normal as well.
Transsphenoidal biopsy of the skull base mass was per-
formed and demonstrated an inflammatory infiltrate with
lymphocytes and slight increase in B cells with inter-
spersed macrophages and plasma cells (Fig. 3a, b). Stain-
ing for CD20 and CD3 revealed a mixture of B and T
cells. Histochemical staining for fungi and mycobacteria
was negative. As the biopsy did not produce conclusive
diagnostic results, a bone marrow biopsy and aspirate
were performed to look for lymphomatous changes.
Cytology and flow cytometry of the aspirate were both
normal. Adalimumab was then discontinued as it was felt
it could have been a possible culprit in the development of
the skull base lesion (it has been previously reported to be
associated with rare forms of lymphoma as well as
increased incidence of sarcoidosis) [1–3].
One month after the biopsy was performed, visual acuity
spontaneously improved to 20/40 on the right. Motility
deficits had all resolved and fundoscopy remained normal.
There was a mild anterior uveitis with a few anterior vitre-
ous cells and no posterior vitritis in either eye.
Lack of definitive diagnosis prompted repeat of the CTscan
of the brain and orbits which was unchanged. At this point, a
review of possible differential diagnosis led to another look at
the results of the biopsy. IgG4 stains were requested and
demonstrated an IgG:IgG4 ratio of more than 40% as well as
more than 30 IgG4 positive plasma cells per high-power field
(Fig. 4a, b). Serum IgG-4 levels were normal.
As the patient recovered spontaneously and has not
had any future relapses, no treatment was initiated and
he has been followed with observation only. The panu-
veitis has remained controlled with topical steroid drops
over the past 2 years, after the initial presentation.
Conclusions
To our knowledge, this is the first reported case of
panuveitis without scleral involvement associated with
IgG4-RD.
IgG4-RD is an emerging entity that has been described
and reported on extensively in the recent years. It is
characterized by tumefactive lesions, dense lymphoplas-
macytic infiltrate abundant in IgG4-positive plasma cells,
and fibrosis with typical storiform pattern and oblitera-
tive phlebitis, although the latter is only intermittently
observed, depending on the affected organs [4, 5]. The
disease was originally described in 2001 in a cohort of
Japanese patients presenting with autoimmune pancrea-
titis and a raised serum IgG4 level [2, 3]. Since then, it
has been described in nearly all organs, including the
lungs, liver, kidney, and thyroid [4, 6–9].
Fig. 1 Axial T1 (a) and T2 (b, c) weighted magnetic resonance imaging, pre-gadolinium, showing an osteodestructive skull base process, with a
lesion centered around the right sphenoid sinus and extending through the cavernous sinus into the adjacent meninges and right superior
orbital fissure. Axial (d) T1 weighted magnetic resonance imaging, post-gadolinium, showing the focus of enhancement of the lesion
Fig. 2 Axial computed tomography scanning of the brain
demonstrating an asymmetric thickening in the left posterior
cavernous sinus extending to the right anterior cavernous sinus and
right orbital apex
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Diagnostic criteria for IgG4-RD are still incompletely
defined. An international consensus statement [10] had
suggested three different levels of diagnostic classifica-
tion for IgG4-RD: histologically highly suggestive of
IgG4-RD, probable histologic features of IgG-RD, or
insufficient histologic evidence of IgG4-RD. Other classi-
fications [11] have attempted to include the serum IgG4
levels in the diagnostic criteria, but the serum levels can
be normal in as much as 30–40% of patients (as they were
in our case) with IgG4-RD thus rendering this diagnostic
tool unsupportive in this cluster of patients [5, 12].
From an ophthalmological point of view, IgG4-RD
most often affects the orbit or lacrimal gland [4, 9, 13].
A Japanese study reviewed 65 cases with IgG4-related
ophthalmic diseases (ROD) [14] and reported 31 cases
(57.7%) that had only lacrimal gland involvement, with
the remaining 34 cases (52.3%) involving ocular adnexa:
trigeminal nerve, extraocular muscles, orbit, eyelid and
nasolacrimal duct [14]. Rare cases of conjunctival,
scleral, and optic nerve involvement have also been
reported [7, 15, 16].
Nearly half of the patients presenting with ocular IgG4-
related ophthalmic disease will also have extraocular man-
ifestations in other organs, and it is suggested that all
patients should be evaluated for the salivary gland enlarge-
ment, lymphadenopathy, and lung, liver, and renal in-
volvement [16]. Whole-body fluorodeoxyglucose positron
emission tomography/computed tomography (FDG-PET/
CT) is a valuable imaging study to assess for the extraocu-
lar manifestations of the disease [17].
In the past few years, associations between granuloma-
tous diseases, such as sarcoidosis, adult orbital xantho-
granuloma and granulomatosis with polyangiitis, and
IgG4-RD have been described [15, 18–21]. These cases
demonstrate a possible overlap between these two condi-
tions, although this is still not clearly understood. Inter-
estingly, lymphoma has been associated with IgG4-RD
and the latter seems to increase the risk of lymphoma
[17, 22–24]. Therefore, granulomatous disease and
lymphoma should be considered in the differential of
IgG4-RD. In the case presented here, both entities
were initially considered but it was erroneously pre-
sumed that they were related to adalimumab use and
not directly to IgG4-RD.
There is no clear consensus on the treatment of IgG4-
RD. Spontaneous resolution has been described in the
literature [25] and in our case, although the skull base
lesion has remained unchanged, with the exception of
mild panuveitis, the disease remained quiescent without
treatment. Recurrence, however, is possible at any point
in time. Corticosteroids are the first line of treatment
and have been shown to be effective in treating the
disease, although the relapse rate can be higher in
patients treated with steroids [26]. Steroid-sparing
agents have also been used successfully in treating IgG4
with rituximab (anti-CD20 monoclonal antibody) being
Fig. 3 a, b Transsphenoidal biopsy of the skull base mass demonstrating an inflammatory infiltrate with lymphocytes and slight increase in B cells
with interspersed macrophages and plasma cells
Fig. 4 IgG stains (a) IgG4 stains (b) demonstrated an IgG:IgG4 ratio of more than 40% as well as more than thirty IgG4-positive plasma cells per
high-power field
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the most successful. Dramatic responses to this anti-
CD20 monoclonal antibody have been reported in the
first month of treatment [27, 28]. Treatment with rituxi-
mab was suggested for our patient but, since he has
remained largely asymptomatic, it was not used. Low-
dose radiotherapy has also been described with variable
response [17, 29].
Our report emphasizes the importance of keeping
IgG4-RD in the list of differential diagnosis for patients
with panuveitis and especially for patients presenting
with panuveitis and eye motility abnormalities as these
combinations of clinical findings are difficult to explain
by a single pathological entity otherwise.
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